Cryo-Cell International, Inc. Reports Fiscal First Quarter 2026 Financial Results
Cryo-Cell International a pioneer in the cord blood banking industry, has announced its financial results for the first quarter of fiscal year 2026, which ended on February 28, 2026. As one of the earliest innovators in private stem cell preservation, the company continues to play a significant role in advancing cellular therapies and biostorage solutions worldwide.
The company’s latest quarterly report reflects a period of modest revenue decline and reduced profitability compared to the same period in the previous year. Despite these challenges, Cryo-Cell maintains a strong operational foundation and continues to expand its footprint in both private and public cord blood banking services.
Revenue Performance
During the first quarter of fiscal 2026, Cryo-Cell reported total revenues of $7.68 million, representing a slight decrease from $7.97 million recorded in the first quarter of fiscal 2025. This decline reflects minor shifts across the company’s revenue streams, particularly in its public banking segment.
A significant portion of the company’s revenue continues to come from its core services—processing and storage fees. In the first quarter of 2026, these services generated $7.64 million, compared to $7.87 million in the same period last year. This segment remains the backbone of Cryo-Cell’s business model, highlighting the ongoing demand for long-term stem cell preservation among families.
Product-related revenue contributed $36,000 during the quarter, showing a slight increase from $21,000 in the prior year. Although relatively small in proportion, this growth suggests incremental diversification in the company’s offerings.
Public banking revenue experienced a notable decline, dropping to approximately $1,400 from $82,000 in the first quarter of fiscal 2025. This reduction may reflect variability in donation activity, partnerships, or utilization rates within the public banking program.
Overall, while total revenue saw a marginal dip, Cryo-Cell’s primary revenue stream—processing and storage—remains stable, underscoring the resilience of its core business operations.
Net Income and Profitability
In terms of profitability, Cryo-Cell reported net income of approximately $47,000, or $0.01 per basic and diluted common share, for the three months ended February 28, 2026. This marks a significant decrease compared to the $283,000, or $0.03 per share, recorded during the same period in fiscal 2025.
The decline in net income can likely be attributed to a combination of reduced revenue and potential increases in operating expenses, although detailed cost breakdowns were not specified. Despite the drop, the company remained profitable, which is an important indicator of financial stability in a competitive and evolving healthcare sector.
Maintaining profitability, even at a lower level, reflects Cryo-Cell’s disciplined financial management and its ability to sustain operations while navigating market fluctuations.
Company Background and Industry Leadership
Founded in 1989, Cryo-Cell International, Inc. holds the distinction of being the world’s first private cord blood bank, having begun separating and storing stem cells as early as 1992. Over the decades, the company has established itself as a leader in the preservation of umbilical cord blood and tissue, which are rich sources of stem cells used in medical treatments.
Today, Cryo-Cell stores more than 250,000 cord blood and cord tissue specimens, safeguarding these valuable biological resources for newborns and potentially other family members. These stored stem cells may play a critical role in future medical treatments, including therapies for blood disorders, immune deficiencies, and certain genetic conditions.
Public Banking Program and Partnerships
In addition to its private banking services, Cryo-Cell operates a public cord blood banking program in collaboration with Duke University. This initiative allows donated cord blood to be used for patients in need of transplants, contributing to life-saving treatments across the globe.
To date, Cryo-Cell’s public bank has supported over 700 transplants, demonstrating its meaningful impact on public health. The company also operates a cord blood donation site at Cedars-Sinai Hospital in Los Angeles, one of the most prominent medical institutions in the United States. This strategic presence enhances accessibility for donors and strengthens Cryo-Cell’s role in advancing stem cell therapy.
Regulatory Compliance and Accreditations
Cryo-Cell’s facilities meet rigorous regulatory and quality standards. The company is FDA registered and compliant with current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP). It is also licensed in all U.S. states that require licensure for cord blood banking.
In addition to regulatory compliance, Cryo-Cell has earned several prestigious accreditations. It is accredited by the AABB (Association for the Advancement of Blood & Biotherapies), a globally recognized organization that sets high standards for blood and biotherapy services.
Notably, Cryo-Cell was the first private cord blood bank in the United States to receive accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT). This certification reflects adherence to some of the most stringent quality standards in the industry, reinforcing the company’s commitment to excellence.
Technological Innovation
A key differentiator for Cryo-Cell is its exclusive rights to PrepaCyte-CB, an advanced cord blood processing technology. This proprietary method is designed to maximize stem cell recovery and improve the quality of stored samples, which can be critical for successful therapeutic outcomes.
By leveraging cutting-edge technology, Cryo-Cell continues to enhance its service offerings and maintain a competitive edge in the rapidly evolving field of regenerative medicine.
Mission and Strategic Vision
Cryo-Cell’s mission extends beyond storage services. The company aims to deliver high-quality cryopreservation solutions, develop and administer cellular therapies, and ultimately improve patient outcomes worldwide.
Its strategic focus includes:
- Expanding access to stem cell preservation services
- Advancing research and development in cellular therapies
- Maintaining high standards of quality and compliance
- Offering cost-effective and reliable biostorage solutions
Through these initiatives, Cryo-Cell seeks to remain at the forefront of the biotechnology and healthcare sectors.
While the first quarter of fiscal 2026 presented some financial challenges, Cryo-Cell remains well-positioned for long-term growth. The steady demand for cord blood banking, combined with advancements in regenerative medicine, continues to support the company’s core business.
As awareness of stem cell therapies grows and new medical applications emerge, Cryo-Cell is likely to benefit from increased adoption of its services. Its strong foundation, industry leadership, and commitment to innovation provide a solid platform for future expansion.
Cryo-Cell International, Inc.’s first quarter results for fiscal 2026 highlight both the challenges and resilience of a company operating in a specialized healthcare segment. Despite a slight decline in revenue and net income, the company continues to demonstrate stability, maintain profitability, and uphold its reputation as a pioneer in cord blood banking.
With a robust infrastructure, strategic partnerships, and a forward-looking mission, Cryo-Cell remains a key player in the global effort to harness the power of stem cells for improved healthcare outcomes.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. The Company currently stores over 250,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and possibly other members of their Families. In addition to its private bank, Cryo-Cell International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 700 transplants and operates a cord blood donation site at one of the country’s most prominent hospitals, Cedars–Sinai Hospital in Los Angeles. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell has the exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology.
Cryo-Cell’s mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.
